The efficacy and tolerability of mesalazine granules vs. placebo

• Research type

  Research Study

• Full title

  Double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurrence of diverticulitis

• IRAS ID

  3414

• Contact name

  Robin Charles Spiller

• Contact email

  robin.spiller@nottingham.ac.uk

• Sponsor organisation

  Dr. Falk Pharma GmbH

• Eudract number

  200700068022

• Clinicaltrials.gov Identifier

  NCT00695643

• Research summary

  Research Summary not published at request of researcher

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  08/H1010/99

• Date of REC Opinion

  8 Apr 2009

• REC opinion

  Further Information Favourable Opinion